Health conditions
(Data source: WHO)
Coronary artery disease
Circulatory System
Chronic ischaemic heart disease
Interventions (Data source: WHO)
Ivabradine/placebo tablets for up to 48 months.
Inclusion/Exclusion Criteria
(Data source: WHO)
Inclusion criteria:
1. Aged 55 years or older
2. Male or female
3. Patients with stable coronary artery disease without clinical heart failure
4. Sinus rhythm and resting heart rate equal or higher than 70 bpm
Exclusion criteria:
1. Unstable cardiovascular condition
2. Contra-indication to ivabradine
-
Further information on trial
Date trial registered
Sep 21, 2009
Incorporation of the first participant
Sep 1, 2009
Recruitment status
Completed
Academic title
(Data source: WHO)
Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure: a randomised double-blind placebo-controlled international multicentre study
Type of trial
(Data source: WHO)
Interventional
Design of the trial
(Data source: WHO)
Randomised double-blind placebo-controlled trial (Treatment)
Phase
(Data source: WHO)
Not Applicable
Primary end point
(Data source: WHO)
The effect of ivabradine on cardiovascular events, measured up to 48 months.
Secundary end point
(Data source: WHO)
Measured up to 48 months:
1. Efficacy
2. Safety
Contact information
(Data source: WHO)
Institut de Recherches Internationales Servier (France)
Trial results
(Data source: WHO)
Results summary
no information available yet
Link to the results in the primary register
no information available yet
Information on the availability of individual participant data
no information available yet
Trial sites
Countries
(Data source: WHO)
Argentina, Armenia, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Italy, Kazakhstan, Korea, Latvia, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Uruguay, Viet Nam
Contact for further information on the trial
Contact for scientific information
(Data source: WHO)
Kim
Fox
Sydney Street
Further trial identification numbers
Secondary ID (Data source: WHO)
2009-011360-10
NCT02446990
CL3-16257-083
Back to overview
